The Use Of Continuous Chromatography In Effective Process Design To Be Presented By Catalent Biologics Expert At PREP Symposium

SOMERSET, N.J. – July 2, 2019 — Catalent, the leading global provider of advanced delivery technologies, and development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that Ben Kester, Manager and Senior Scientist, Purification Development, Catalent Biologics, will present at the upcoming 32 nd International Symposium on Preparative and Process Chromatography (PREP Symposium) at the Hyatt Regency Baltimore Inner Harbor, Baltimore, Maryland on July 7 – 10, 2019.

On Monday, July 8 at 4:20 p.m., Mr. Kester will present “ Strategies for Process Design: Unlocking Combinations with Continuous Chromatography and Cutting-Edge Technologies ”. The session will explore the latest technologies available when designing a process, with a focus on continuous chromatography, highlighting how the technique can provide a range of adjustability to improve timelines and efficiency. Mr. Kester will include case studies in the presentations to demonstrate the technology’s use with a number of products with different challenges, such as stability issues.

In his role at Catalent, Mr. Kester is responsible for downstream purification development at the Catalent Biologics facility in Bloomington, Indiana. He oversees process design and characterization and facilitates technical transfer to cGMP production. He has a bachelor’s degree in cellular and molecular biology from Grand Valley State University, Allendale, Michigan and a master’s degree in biochemistry from Indiana University Bloomington.

For more information, please visit .

To arrange a meeting with Mr. Kester at the event, contact Richard Kerns at NEPR - .

Media Contacts:
Chris Halling
+44 (0)7580 041073

Richard Kerns, NEPR
+44 (0)161 728 5880


Catalent Biologics has 20+ years’ experience in development, manufacturing, and analytical services for new biological entities, biosimilars, and antibody-drug conjugates. Catalent has worked with 600+ mAbs and 80+ proteins, and more than 115 clinical trials and 11 marketed products have used GPEx ® cell line engineering technology. A further 20 commercially-approved products have employed Catalent Biologics’ capabilities through to aseptic fill/finish. Using advanced protein improvement technology and tailored solutions from DNA through to clinical and commercial supply, Catalent Biologics brings better biologic treatments to patients, faster. For more information, visit  


Catalent is the leading global provider of advanced delivery technologies and development and manufacturing solutions for drugs, biologics, gene therapies and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal year 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit .

More products. Better treatments. Reliably supplied.™